8+ min ago (142+ words) New Delhi, Nov 25 (PTI) Zydus Lifesciences on Tuesday said it has received approval from the US health regulator to market a generic medication to treat high blood pressure. The company has received approval from the US Food and Drug Administration (USFDA) for Verapamil Hydrochloride extended-release tablets in multiple strengths, the drug firm said in a statement. Verapamil Hydrochloride extended-release tablets are used to lower high blood pressure, which helps reduce the risk of serious heart problems like strokes and heart attacks. The tablets will be produced at the company's Baddi-based plant in Himachal Pradesh. As per the IQVIA MAT September 2025 data, Verapamil Hydrochloride extended-release tablets had annual sales of USD 24.5 million in the US. Shares of Zydus Lifesciences on Tuesday ended marginally up at Rs 927.50 apiece on BSE. PTI MSS MSS BAL BAL...

9+ min ago (93+ words) A Notice by the National Institutes of Health on 11/25/2025 This PDF is FR Doc. 2025-20984 as it appeared on Public Inspection on 11/24/2025 at 8:45 am. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Immunology of Hypersensitivity and Host Defense. Date: January 20, 2025. Time: 10:00 a.m. to 5:00 p.m. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Dated: November 20, 2025. [FR Doc. 2025-20984 Filed 11-24-25; 8:45 am]...

10+ min ago (125+ words) A Notice by the National Institutes of Health on 11/25/2025 This PDF is FR Doc. 2025-21010 as it appeared on Public Inspection on 11/24/2025 at 8:45 am. Name of Committee: Applied Immunology and Disease Control Integrated Review Group; Vaccines Against Infectious Diseases Study Section. Date: January 26-27, 2026. Time: 10:00 a.m. to 5:00 p.m. Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Jian Wang, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4218, MSC 7812, Bethesda, MD 20892, 301-213-9853, [email protected]. Dated: November 21, 2025. [FR Doc. 2025-21010 Filed 11-24-25; 8:45 am]...

10+ min ago (87+ words) A Notice by the National Institutes of Health on 11/25/2025 This PDF is FR Doc. 2025-20985 as it appeared on Public Inspection on 11/24/2025 at 8:45 am. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Drug Development. Date: January 29, 2026. Time: 9:00 a.m. to 6:00 p.m. Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Dated: November 20, 2025. [FR Doc. 2025-20985 Filed 11-24-25; 8:45 am]...

10+ min ago (102+ words) A Notice by the National Institutes of Health on 11/25/2025 This PDF is FR Doc. 2025-21038 as it appeared on Public Inspection on 11/24/2025 at 8:45 am. Date: December 18, 2025. Time: 1:00 p.m. to 4:00 p.m. Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Rupali Das, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-0023, [email protected]. Dated: November 21, 2025. [FR Doc. 2025-21038 Filed 11-24-25; 8:45 am]...

12+ min ago (109+ words) A Notice by the National Institutes of Health on 11/25/2025 This PDF is FR Doc. 2025-21022 as it appeared on Public Inspection on 11/24/2025 at 8:45 am. Date: January 7-8, 2026. Time: 09:30 a.m. to 06:00 p.m. Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Angela Y. Ng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 710-C, MSC 7806, Bethesda, MD 20892, 301-435-1715, [email protected]. Dated: November 21, 2025. [FR Doc. 2025-21022 Filed 11-24-25; 8:45 am]...

12+ min ago (122+ words) A Notice by the National Institutes of Health on 11/25/2025 This PDF is FR Doc. 2025-21080 as it appeared on Public Inspection on 11/24/2025 at 8:45 am. Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. Date: December 18, 2025. Time: 9:00 a.m. to 7:00 p.m. Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Yuanyi Feng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892, (301) 594-1180, [email protected]. Dated: November 21, 2025. [FR Doc. 2025-21080 Filed 11-24-25; 8:45 am]...

14+ min ago (699+ words) [Business News | HemeNext 2025: India]Get latest articles and stories on Business at LatestLY. Gurgaon (Haryana) [India], November 25: HemeNext 2025, held at The Westin Hotel, Gurgaon on the 22nd and 23rd of November, welcomed nearly 300 delegates from across the country, making it one of India's most anticipated gatherings in the field of hematology. Conceptualised and led by Dr Rahul Bhargava, the conference stood out for its meticulous planning, scientific depth and a strong focus on improving outcomes for patients battling leukaemia, lymphoma, myeloma and other complex blood disorders. Business News | HemeNext 2025: India's Premier Hematology Conference Unveils the Future of Genomics, Transplants and AI in Blood Cancer Treatment Get latest articles and stories on Business at LatestLY. Gurgaon (Haryana) [India], November 25: HemeNext 2025, held at The Westin Hotel, Gurgaon on the 22nd and 23rd of November, welcomed nearly 300 delegates from across the country, making it one of India's…...

53+ min ago (923+ words) It's important to keep up with these health checks " from vaccinations to breast cancer screening With December drawing near, it is an ideal time to address any outstanding health admin before the Christmas festivities begin. Proactive health management becomes increasingly vital as we age. "While genetics play a role, advancing years, environmental exposure, and lifestyle choices can significantly impact our wellbeing," says Dr Angela Rai, GP at The London General Practice. "Advanced screening techniques, expert advice and timely interventions can help you stay proactive about your health, whether you're in your 60s or your 90s." As 2026 looms, here are eight essential health checks to consider for your agenda. Viruses are rife this time of year, so it's important to stay up to date with vaccinations. The flu vaccine, the COVID-19 booster, the pneumococcal vaccine and the shingles vaccine are the main jabs…...

1+ hour, 8+ min ago (779+ words) Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trialKisqali NATALEE and MONALEESA data add to evidence of long-term benefits for early and metastatic breast ca...